EZH2 and urinary bladder cancer: For the remaining tumors with SWI/SNF mutations, EZH2 inhibition with and without cisplatin might represent an effective option, as it has been recently demonstrated in bladder cancer cells and xenografts, through a mechanism that activates a natural killer (NK) cell-based immune response [22].